Repurposing drugs for treatment of tuberculosis (TB): a role for non-steroidal anti-inflammatory drugs.

Article, Other literature type English OPEN
Maitra, Arundhati ; Bhakta, Sanjib ; Evangelopoulos, Dimitrios (2016)

Introduction \ud The number of cases of drug-resistant Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), has risen rapidly in recent years. This has led to the resurgence in repurposing existing drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), for anti-TB treatment. \ud Sources of data\ud Evidence from novel drug screening in vitro, in vivo, pharmacokinetic/pharmacodynamics analyses and clinical trials has been used for the preparation of this systematic review of the potential of NSAIDs for use as an adjunct in new TB chemotherapies. \ud Areas of agreement\ud Certain NSAIDs have demonstrated inhibitory properties towards actively-replicating, dormant and drug-resistant clinical isolates of M. tuberculosis cells. \ud Areas of controversy \ud NSAIDs are a diverse class of drugs, which have reported off-target activities and their endogenous antimicrobial mechanism(s) of action is still unclear. \ud Growing points \ud It is essential that clinical trials of NSAIDs continue, in order to assess their suitability for addition to the current TB treatment regimen. Repurposing molecules such as NSAIDs is a vital, low-risk strategy to combat the trend of rapidly increasing antibiotic resistance.
  • References (17)
    17 references, page 1 of 2

    Organization WH. Global tuberculosis report 2015. 2015

    Burman WJ. Rip Van Winkle Wakes Up: Development of Tuberculosis Treatment in the 21st Century. Clinical Infectious Diseases 2010; 50: S165-S172

    Maitra A, Bhakta S. TB Summit 2014: prevention, diagnosis, and treatment of tuberculosis-a meeting report of a Euroscicon conference. Virulence 2014; 5: 638-44 Maitra A, Danquah CA, Scotti F et al. Tackling tuberculosis: Insights from an international TB Summit in London. Virulence 2015; 6: 581-92

    Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40 Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006; 25: 420-8

    Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3: 673-83

    Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013; 12: 388-404

    Languillon J. The effects ot thalidomide on leprosy reaction. International Journal of Leprosy 1971; 39: 590-592

    Schoeman JF, Fieggen G, Seller N, Mendelson M, Hartzenberg B. Intractable Intracranial Tuberculous Infection Responsive to Thalidomide: Report of Four Cases. Journal of Child Neurology 2006; 21: 301-308

    Oprea TI, Mestres J. Drug repurposing: far beyond new targets for old drugs. AAPS J 2012; 14: 759-63

    Kinnings SL, Xie L, Fung KH, Jackson RM, Bourne PE. The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol 2010; 6: e1000976 Palomino JC, Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J Antimicrob Chemother 2013; 68: 275-83

  • Related Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark